

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 2, 2022

**Consolidated Financial Summary
for the First Six Months of the Fiscal Year Ending March 31, 2023
(Under Japanese GAAP)**

Listed Company: Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: Tokyo Stock Exchange)

Code Number: 4559

(URL: <https://www.zeria.co.jp/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date to submit the Quarterly Securities Report: November 7, 2022

Scheduled date to commence dividend payments: December 1, 2022

Preparation of supplementary documents to the quarterly financial results: Yes

Holding of quarterly financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2022 through September 30, 2022)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | |
|--------------------|-------------|------|------------------|-------|-----------------|-------|---|------|
| | Million yen | % | Million yen | % | Million yen | % | Million yen | % |
| Six months ended | | | | | | | | |
| September 30, 2022 | 33,712 | 17.9 | 5,894 | 120.6 | 5,182 | 66.3 | 3,998 | 89.0 |
| September 30, 2021 | 28,606 | 12.1 | 2,672 | 67.2 | 3,116 | 138.4 | 2,115 | 52.4 |

Note: Comprehensive income: For the six months ended September 30, 2022: 8,069 million yen [267.7%]

For the six months ended September 30, 2021: 2,194 million yen [10.9%]

| | Basic earnings per share | Diluted earnings per share |
|--------------------|--------------------------|----------------------------|
| Six months ended | Yen | Yen |
| September 30, 2022 | 90.41 | – |
| September 30, 2021 | 46.65 | – |

(2) Consolidated Financial Position

| | Total assets | Net assets | Equity ratio | Net assets per share |
|--------------------|--------------|-------------|--------------|----------------------|
| As of | Million yen | Million yen | % | Yen |
| September 30, 2022 | 134,407 | 61,822 | 45.8 | 1,395.01 |
| March 31, 2022 | 124,282 | 55,092 | 44.2 | 1,236.09 |

Reference: Equity: As of September 30, 2022: 61,581 million yen

As of March 31, 2022: 54,894 million yen

2. Dividends

| | Annual dividends | | | | |
|---------------------------|------------------|----------------|---------------|----------|-------|
| | First quarter | Second quarter | Third quarter | Year-end | Total |
| Year ended | Yen | Yen | Yen | Yen | Yen |
| March 31, 2022 | – | 17.00 | – | 18.00 | 35.00 |
| Year ending | – | 18.00 | | | |
| March 31, 2023 | | | | | |
| Year ending | | | – | 18.00 | 36.00 |
| March 31, 2023 (Forecast) | | | | | |

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2023 (April 1, 2022 through March 31, 2023)

(Percentage figures indicate changes from the same period of the previous year.)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | | Basic earnings per share |
|-----------|-------------|------|------------------|------|-----------------|------|---|------|--------------------------|
| | Million yen | % | Million yen | % | Million yen | % | Million yen | % | Yen |
| Full year | 66,000 | 10.9 | 7,000 | 10.0 | 7,000 | 17.9 | 5,600 | 41.4 | 126.73 |

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Changes in significant subsidiaries during the six months ended September 30, 2022 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):

As of September 30, 2022: 53,119,190 shares As of March 31, 2022: 53,119,190 shares

2) Number of shares of treasury shares as of the end of the term:

As of September 30, 2022: 8,974,949 shares As of March 31, 2022: 8,709,322 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the six months ended September 30, 2022: 44,229,546 shares

For the six months ended September 30, 2021: 45,360,392 shares

* Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or an Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.